Hyperfine Announces Data From Stroke Detection With Swoop System, Identifies Lesions As Small As 2.8 MM, Achieves 100% Sensitivity, 100% Specificity For Lesions Over 1 ML

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced results from the largest data set to date evaluating stroke detection with the Swoop® system. This data provides strong evidence supporting the use of AI-powered portable MRI for stroke detection in multiple clinical settings, including the emergency department.

The prospective multi-center observational study, published in the November issue of Stroke: Vascular and Interventional Neurology (SVIN), evaluates 95 patients, combining data from the ACTION PMR study at Massachusetts General Hospital and Buffalo General Medical Center, with data from Yale New Haven Hospital. The study evaluated the sensitivity and specificity of ischemic lesion detection, comparing both the original and next-generation Swoop® system scanners, along with a comparison of two types of DWI sequences, a sequence that is critical for stroke detection.